RhumbLine Advisers
ZBIO

RhumbLine Advisers’s Zenas BioPharma ZBIO Stock Holding History

RhumbLine Advisers’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$524K Buy
26,813
+4,867
+22% +$109K ﹤0.01% 2583
2025
Q4 		$797K Buy
21,946
+732
+3% +$24.1K ﹤0.01% 2365
2025
Q3 		$471K Buy
21,214
+1,493
+8% +$24.3K ﹤0.01% 2736
2025
Q2 		$191K Buy
19,721
+8,207
+71% +$79.9K ﹤0.01% 3249
2025
Q1 		$91K Sell
11,514
-27,428
-70% -$215K ﹤0.01% 3418
2024
Q4 		$319K Buy
+38,942
New +$607K ﹤0.01% 2956

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

RhumbLine Advisers's ZBIO Position: Q1 2026 in Review

RhumbLine Advisers increased its Zenas BioPharma (ZBIO) stake by 22% in Q1 2026, buying an estimated $109K and bringing the position to 26,813 shares worth $524K. The position accounts for ﹤0.01% of the portfolio, ranked #2583.

RhumbLine Advisers first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $797K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • RhumbLine Advisers held 26,813 shares of Zenas BioPharma worth $524K as of Q1 2026.
  • RhumbLine Advisers bought 4,867 Zenas BioPharma shares in Q1 2026, an estimated $109K.
  • Zenas BioPharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2583 holding.
  • RhumbLine Advisers first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • RhumbLine Advisers's Zenas BioPharma position peaked at $797K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.